Diasorin said Tuesday that the firm's first quarter revenues jumped 8 percent year over year with growth across the company's immunodiagnostics, molecular diagnostics, and licensed technologies businesses.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025.

Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025.

The 2024 annual reports of major Chinese IVD companies released.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 29, 2025.

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025.

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 28, 2025.

BioMérieux's year-over-year sales grew approximately 14 percent for the first quarter, the firm reported on Thursday, prompting it to confirm its previous full-year revenue guidance.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earnings per share (EPS), reflecting strong performances across many growth drivers.